So, you may have heard that the DEA rescheduled CBD. While CBD was never actually explicitly scheduled on the Controlled Substances Act also known as the CSA, it has been considered “scheduled” by many due to its association with cannabis.
Cannabis as you probably know is still classified as a schedule 1 substance according to the CSA. This is alongside illicit, deadly street drugs such as heroin, LSD, and ecstasy.
The recent announcement that you may have heard about was pertaining to a new pharmaceutical CBD based epilepsy drug called Epidiolex.
This drug which was recently approved by the FDA was classified as a schedule 5 substance on the CSA by the DEA in late September.
This places the pharmaceutical cannabis-derived drug in the same classification as Robitussin and Lyrica, while the natural plant is still considered to be of no medical value per the CSA.
Here is what you need to know about this recent move by the DEA.
This change will allow a pharmaceutical company to make millions in profits each year due to the $32,500 price tag attached to the annual use of the drug.
This is quite unfortunate considering that the natural plant that can provide the same effects for a much lower cost is still demonized and will cost thousands of people jail time and much more this year alone.Posted: Thursday, October 11th, 12:00pm a month ago
Ashley is a freelance cannabis writer and the co-owner of CannaLance. Her passion for sharing education and truth surrounding cannabis stems from a personal loss. Ashley has always had an elevated relationship with cannabis but it wasn't until 2015 that she turned that passion and relationship into a career as a cannabis writer.